Trevi Therapeutics (NASDAQ:TRVI) Receives “Buy” Rating from HC Wainwright
Trevi Therapeutics (NASDAQ:TRVI – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $12.50 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 89.11% from the company’s current price. TRVI has been […]
Trevi Therapeutics (NASDAQ:TRVI – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $12.50 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 89.11% from the company’s current price. TRVI has been […]
